Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

References

• Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi: 10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801–1809. doi: 10.1016/S0140-6736(03)13405-8
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi: 10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197. doi: 10.1016/S0140-6736(15)01123-X
   PubMed Web of Science ®Google Scholar
• Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J. 2016;14(Suppl 1):30. doi: 10.1186/s12959-016-0103-3
   PubMedGoogle Scholar
• Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72. doi: 10.1177/2040620712464509
   PubMedGoogle Scholar
• Prezotti ANL, Frade-Guanaes JO, Yamaguti-Hayakawa GG, et al. Immunogenicity of current and new therapies for hemophilia A. Pharmaceuticals. 2022;15(8):911. doi: 10.3390/ph15080911
   Web of Science ®Google Scholar
• Jardim LL, Chaves DG, Rezende SM. Development of inhibitors in hemophilia A: An illustrated review. Res Pract Thromb Haemost. 2020;4(5):752–760. doi: 10.1002/rth2.12335
   PubMed Web of Science ®Google Scholar
• Bray G. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII. Ann Hematol. 1994;68(Suppl 3):S29–34. doi: 10.1007/BF01774527
   PubMedGoogle Scholar
• Liesner RJ, Abraham A, Altisent C, et al. Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: Final results of the NuProtect study. Thromb Haemost. 2021;121(11):1400–1408. doi: 10.1055/s-0040-1722623
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13(5):606–612. doi: 10.1111/j.1365-2516.2007.01518.x
   PubMed Web of Science ®Google Scholar
• Walsh CE, Soucie JM, Miler CH, et al. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–405. doi: 10.1002/ajh.23957
   PubMed Web of Science ®Google Scholar
• Nerich V, Tissot E, Faradji A, et al. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharm World Sci. 2008;30(3):287–292. doi: 10.1007/s11096-007-9181-4
   PubMedGoogle Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8(6):1256–1265. doi: 10.1111/j.1538-7836.2010.03823.x
   PubMed Web of Science ®Google Scholar
• Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost. 2007;5(Suppl 1):143–150. doi: 10.1111/j.1538-7836.2007.02474.x
   PubMedGoogle Scholar
• Jefferis R. Posttranslational Modifications and the Immunogenicity of Biotherapeutics. J Immunol Res. 2016;2016:5358272. doi: 10.1155/2016/5358272
   PubMed Web of Science ®Google Scholar
• Kozma GT, Shimizu T, Ishida T, et al. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154-155:163–175. doi: 10.1016/j.addr.2020.07.024
   PubMed Web of Science ®Google Scholar
• Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247–251. doi: 10.1055/s-0038-1653759
   PubMed Web of Science ®Google Scholar
• Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121(6):1039–1048. doi: 10.1182/blood-2012-07-444877
   PubMed Web of Science ®Google Scholar
• Lubich C, Allacher P, de la Rosa M, et al. The mystery of antibodies against polyethylene glycol (PEG) – what do we know? Pharm Res. 2016;33(9):2239–2249. doi: 10.1007/s11095-016-1961-x
   PubMed Web of Science ®Google Scholar
• Hay CRM, DiMichele D. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335–1344. doi: 10.1182/blood-2011-08-369132
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4693–4697. doi: 10.1182/blood-2006-11-056317
   PubMed Web of Science ®Google Scholar
• Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11–17. doi: 10.1182/blood-2008-06-160432
   PubMed Web of Science ®Google Scholar
• Stidl R, Fuchs S, Bossard M, et al. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates. Haemophilia. 2016;22(1):54–64. doi: 10.1111/hae.12762
   PubMed Web of Science ®Google Scholar
• Liesner RJ, Abashidze M, Aleinikova O, et al. Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect study. Haemophilia. 2018;24(2):211–220. doi: 10.1111/hae.13320
   PubMed Web of Science ®Google Scholar
• Yaish H, Matsushita T, Belhani M, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia. 2020;26(1):64–72. doi: 10.1111/hae.13883
   PubMed Web of Science ®Google Scholar
• Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 2014;124(23):3389–3397. doi: 10.1182/blood-2014-07-580498
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and Neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–2064. doi: 10.1056/NEJMoa1516437
   PubMed Web of Science ®Google Scholar
• Male C, Konigs C, Dey S, et al. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Adv. 2022;7:620–629. doi: 10.1182/bloodadvances.2022007529
   Web of Science ®Google Scholar
• Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072–1082. doi: 10.1160/TH11-09-0642
   PubMed Web of Science ®Google Scholar
• Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–1827. doi: 10.1182/blood.2020005673
   PubMed Web of Science ®Google Scholar
• Mullins ES, Stasyshyn O, Alvarez-Roman MT, et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23(2):238–246. doi: 10.1111/hae.13119
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–1085. doi: 10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• Miller CH, Benson J, Ellingsen D, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375–382. doi: 10.1111/j.1365-2516.2011.02700.x
   PubMed Web of Science ®Google Scholar